Trial Name	Description
ASCENT-03 BR	Dr. Jacques Raphael A randomized, open-label, phase 3 study of Sacituzumab Govitecan Versus Treatment of Physician's choice in patients with previously untreated, locally advanced, inoperable, or metastatic triple-negative breast cancer whose tumors do not exp
ELISA BR	Dr. Francisco Perera Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined with Clinico-Pathological Features (ELISA Study)
MAC.27 BR	Dr. P. Blanchette COMPASS HER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
EMBER-4 BR	Dr. J. Raphael A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased
ASCENT-04 BR	Dr. Jacques Raphael A randomized, open-label, phase 3 study of Sacituzumab Govitecan and pembrolizumab versus treatment of physicians choice and Pembrolizumab in patients with previously untreated, locally advanced, inoperable, or metastatic triple-negative b
MA.40 BR	Dr. Jacques Raphael A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inh
RHEAL BR	Dr. Francisco Perera Randomized Trial of Hypofractionated LocoRegional Radiotherapy in Breast Cancer and Lymphedema (RHEAL)
RAPID2 BR	Dr. F. Perera Not Open yet - A Randomized Trial of Five-Fraction Partial Breast Irradiation (RAPID2 Trial).
REACT-HOLD BMA	Dr. R. Fernandes A randomised trial comparing continuation or de-escalation of bone modifying agents (BMA) in patients treated for over 2 years for bone metastases from either breast or castration-resistant prostate cancer. (REaCT-Hold BMA)